Delivery Order SPE2DB24D2205-SPE2DB25FEGRX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count) with a ceiling value of $1,625.31. This competitively awarded, firm fixed price delivery order is scheduled for completion by July 24, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,799.69. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through the DLA's open procurement process. The order is scheduled for completion by August 8, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) valued at $2,759.13. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating it was competitively awarded through open competition. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xifaxan 550 mg tablets in quantities of 60 units, with a contract ceiling value of $1,640.75. This firm fixed-price delivery order, which is not set-aside, is scheduled for ultimate completion on August 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract valued at $3,513.96, with an ultimate completion date of August 11, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEGRXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a major pharmaceutical distributor and healthcare solutions provider serving federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen's extensive federal contracting portfolio demonstrates its capability to fulfill varied pharmaceutical requirements across multiple therapeutic domains for Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.9k | 8/22/25 |